IIa B-R In patients with AF at increased risk of stroke (based on CHA2 -VASc risk score of 2 or greater) who have undergone PCI with stenting for ACS, double therapy with inhibitors (clopidogrel) and low-dose rivaroxaban 15 mg daily is reasonable to reduce the risk of bleeding as compared with triple therapy.S7.4-2 NEW: New published data are available. CLINICAL STATEMENTS AND GUIDELINES IIa B-R In patients with AF at increased risk of stroke (based on CHA2 -VASc risk score of 2 or greater) who have undergone PCI with stenting for ACS, double therapy with a inhibitor (clopidogrel) and dabigatran 150 mg twice daily is reasonable to reduce the risk of bleeding as compared with triple NEW: New published data are available. IIb B-R If triple therapy (oral anticoagulant, aspirin, inhibitor) is prescribed for patients with AF who are at increased risk of stroke (based on CHA2 -VASc risk score of 2 or greater) and who have undergone PCI with stenting (drug eluting or bare metal) for ACS, a transition to double therapy (oral anticoagulant and P2Y12 inhibitor) at 4 to 6 weeks may be considered.S7.4-9,S7.4-10 NEW: New published data are available. IIb C Administration of amiodarone or digoxin may be considered to slow a rapid ventricular response in patients with ACS and AF associated with severe LV dysfunction and HF or hemodynamic instability. IIb C Administration of nondihydropyridine calcium antagonists may be considered to slow a rapid ventricular response in patients with ACS and AF only in the absence of significant HF or hemodynamic instability. 